When the API is specified for direct-compression veterinary tablets, the dominant process variable is not the dose but the particle-size distribution and flowability of codeine phosphate hemihydrate. The salt contains approximately 73.7% codeine base, so a formulation intended to deliver 1 mg, 2 mg, or 4 mg codeine base per unit must dispense 1.36 mg, 2.72 mg, or 5.44 mg of codeine phosphate hemihydrate per tablet, assuming assay on anhydrous basis and full salt stoichiometry. The blend is prepared in a 100 L bin blender at 12 rpm for 20 min with microcrystalline cellulose, lactose monohydrate, crospovidone, and magnesium stearate, with the API restricted to 2–8% w/w of the final blend to avoid content uniformity failures. Blend uniformity is confirmed by HPLC assay using Ph. Eur. 2.2.29; release is allowed when ten sampling locations yield RSD ≤ 5.0%. Tablets are compressed on a rotary press equipped with 8 mm B-tooling, applied compression force 8–12 kN, and target hardness 40–70 N. Compliance testing follows Ph. Eur. 2.9.40 for uniformity of dosage units and Ph. Eur. 2.9.3 for dissolution using paddle apparatus 2; in the absence of a harmonised veterinary monograph, the dissolution acceptance criterion is justified from the salt’s aqueous solubility rather than adopted from a human pharmacopoeial monograph. On production-scale lines, two observed failure modes dominate: first, over-lubrication from magnesium stearate above 1.0% w/w can collapse tablet hardness and slow dissolution; second, codeine phosphate hemihydrate can build up on the feed frame of a rotary tablet press when relative humidity exceeds 60%. The compression suite is therefore maintained at 20–25 °C and 35–45% RH. The terminal product types are scored, round, non-sterile veterinary tablets in tamper-evident PVC/aluminium blisters, intended for non-food-producing companion animals because no maximum residue limit is established under Regulation (EU) No 37/2010.

How Terminal Sterilisation Affects Codeine Phosphate Solution Stability

In parenteral compounding, codeine phosphate hemihydrate is dissolved in Water for Injections to produce solutions containing 5 mg/mL or 10 mg/mL codeine base, adjusted with dilute hydrochloric acid to pH 4.0–4.5. Sodium chloride is added to isotonicity at 0.9% w/v, confirmed by freezing-point osmometry according to Ph. Eur. 2.2.35. The primary process conflict is the choice between terminal sterilisation and aseptic filtration. Terminal sterilisation at 121 °C for 15 min imposes a thermal load on the solution; codeine phosphate requires the acidic pH window to keep the active in its salt form, and a drift above 5.5 during heat-up or cooling increases nucleation and precipitation risk. Where terminal sterilisation is selected, the pH is rechecked after the cycle and the lot is released only within the validated range; otherwise, aseptic filtration through a 0.22 µm PVDF membrane is used, with filling under EU GMP Annex 1 Grade A conditions in a Grade C background classified according to ISO 14644-1:2015. Nitrogen overlay is applied during filling to reduce oxidative discolouration; published forced degradation data for this specific veterinary configuration is limited, so pH excursion and oxygen challenge studies are required during process validation. Filling lines used for this API often exhibit batch-to-batch variation in filter membrane compatibility. A PVDF membrane is preferred over nylon because codeine phosphate can adsorb to nylon at low concentration; during filter qualification, the initial 5 mL of filtrate is discarded or the membrane is pre-soaked until HPLC recovery is at or above 95.0%. During scale-up from 5 L to 50 L, pH adjustment before filtration is performed gradually because rapid hydrochloric acid addition can create local concentration gradients that reduce yield through precipitation at the acid entry point. The terminal product types are single-dose 1 mL Type I glass ampoules and multidose 10 mL vials; the solution is intended only for hospital pharmacy compounding under the prescribing cascade of Regulation (EU) 2019/6, not for commercial distribution where no authorised veterinary parenteral product exists.

Oral solutions for canine antitussive use impose different constraints in preservative selection, pH, and packaging than solid dosage forms. A compounded solution is typically prepared at 1 mg/mL codeine base by dissolving codeine phosphate hemihydrate in a citrate buffer of pH 4.2–4.6, with sodium benzoate 0.1% w/v or potassium sorbate 0.1% w/v as preservative, and sorbitol 50–60% w/v as vehicle. Preservative effectiveness is evaluated according to Ph. Eur. 5.1.3; unless the solution is packed as a single-dose unit, the required bacterial and fungal reduction at 7 days and 28 days must be met. The manufacturing sequence uses low-shear mixing: codeine phosphate is dissolved in the buffered vehicle at 20–25 °C, the preservative is added as a pre-dissolved stock solution, and the bulk is passed through a 100 µm nylon mesh to remove undissolved agglomerates. The terminal package is an amber 50 mL or 100 mL PET bottle with a child-resistant cap, paired with an oral dosing syringe marked in 0.5 mL increments. Because the dose margin is narrow and published target animal metabolism data for this specific route is limited, the batch release documentation must state the codeine base content per millilitre and the maximum dose volume per administration rather than relying on a fixed formulation ratio alone. The solution is labelled for non-food-producing companion animals only.

Capsule Fill Weight and Homogeneity Constraints in Split-Container Compounding

The choice of capsule size and powder bed composition is governed by the need to keep codeine content below the threshold where blend segregation exceeds ±5% in fills of 100 or fewer units. For small-breed patients, a capsule is prepared to contain 0.5–2 mg codeine base per unit, diluted with lactose monohydrate and pregelatinised starch in size 3 or size 2 hard gelatin capsules. The process uses geometric dilution: the API is first triturated with an equal mass of excipient in a mortar or low-shear mixer, then sequentially doubled until the final capsule fill weight of 80–120 mg is reached. The fill powder is passed through a 500 µm sieve and mixed for 5 min in a Turbula mixer at 49 rpm. Content uniformity is tested according to Ph. Eur. 2.9.40, and disintegration according to Ph. Eur. 2.9.1. The terminal product type is an unprinted hard gelatin capsule intended for in-clinic administration; because published target animal bioavailability data for this exact formulation is limited, clinical release is typically restricted to veterinary hospital use.

At the bulk intermediate stage, the decision to supply codeine phosphate hemihydrate as a granular premix rather than a finished dosage form shifts the processing burden to the veterinary pharmacy. The granules are produced by wet granulation in a high-shear granulator with lactose monohydrate, maize starch paste, and povidone K30; codeine phosphate hemihydrate is added at 1–5% w/w of the dry granulate batch, corresponding to a dispensing ratio of 1:20 to 1:100 against excipient. The granulation endpoint is determined by impeller power consumption and visual consistency, with a target granule moisture content of 1.5–2.5% after fluid-bed drying at 45–50 °C. Milling through a 1.0 mm screen and sieving to remove fines below 125 µm are used to control segregation. Powder flow is characterised by Ph. Eur. 2.9.36; a flow rate of 15–25 g/s through a 15 mm orifice is accepted for pharmacy transfer operations, though published data for this specific codeine granule configuration is limited. The terminal product types are amber glass screw-cap containers of 50 g or 100 g and double-wall bulk sacks for licensed pharmacy transfer, intended only for extemporaneous preparation of oral powders or solutions and not for resale as a finished drug.

If the API Is Processed as a Bulk Premix, Segregation Is the Controlling Variable

A bulk premix containing codeine phosphate hemihydrate must be assessed as a two-phase system in which the active particles are dispersed in a coarser carrier matrix. The premix is typically formulated at 0.5–2.5% w/w codeine base equivalent on a lactose monohydrate or starch carrier, with colloidal silicon dioxide at 0.2% w/w to reduce interparticle adhesion. The production process uses a ribbon blender or IBC tote blender; active and carrier are first deagglomerated through a 500 µm screen, then blended for 20–30 min at 10–15 rpm. Sampling is performed at 10 defined locations with thief probes, and the lot is released only when HPLC assay by Ph. Eur. 2.2.29 yields RSD ≤ 5.0% across all locations. The premix is then filled into double polyethylene-lined fibre drums with tamper-evident seals and labelled with controlled drug transfer documentation. The terminal product type is a bulk compounding premix for dilution in veterinary pharmacy powders, granules, or liquid vehicles; because codeine lacks a harmonised maximum residue limit in food-producing animals, the premix must be restricted to non-food-producing companion animals and the label must state that food-producing species are excluded.